Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
The established Insight(TM) mHealth Platform, a component of the Stephenson Cancer Center (SCC) mHealth Shared Resource will be used to create the "Symptom Tracker" app. The Symptom Tracker (Insight(TM)) app will enable real-time monitoring of cancer patient symptoms that are consistent with early signs of SARS-CoV-2 infection in this high-risk population by automatically (and securely) transferring this information to health care providers. The primary aim of this study is to determine the feasibility, ease of use, and perceived utility of this app to monitor symptoms and health risk behaviors among cancer patients currently receiving chemotherapy.
Checked against the public recordLast updated Apr 24, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Screening
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Oklahoma
- Interventions being studied
- Other: mHealth Assessments
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Demonstrate \> 6th grade English literacy level (i.e., phone based EMAs require \>6th grade literacy) 2. Present for care at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center 3. Are currently receiving systemic chemotherapy by intravenous infusion or by orally delivered medication 4. Are greater than or equal to 18 years of age 5. Are willing and able to complete surveys on their personal smartphone or a study provided smartphone 6. Are willing and able to provide informed consent Exclusion Criteria: * None
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stephenson Cancer CenterOklahoma City, Oklahoma
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 24, 2023. Always confirm current availability with the study team.